A reference pricing system for Ireland. Usher C, Barry M, Expert Review of Pharmacoeconomics and Outcomes Research. 2012;12(6):675-677.
The use of continuous data versus binary data in MTC models: A case study in rheumatoid arthritis. Schmitz S, Adams R, Walsh C, BMC Medical Research Methodology 2012; 12:167.
The Relative Efficacy of Boceprevir and Telaprevir in the Treatment of HCV Genotype 1.
Jennifer K, Schmitz S, O’Leary A, Walsh C, Bergin C, Norris S, Barry M. Clinical Infectious Diseases. First published online: October 16, 2012
Prescribing trends for dabigatran etexilate in primary care.
McCullagh L and Barry M.Irish Medical Journal 2012; 105 (5): 34-136.
Value-of-Information Analysis to reduce decision uncertainty associated with the choice of thromboprophylaxis after total hip replacement in the Irish Healthcare Setting.
McCullagh L, Walsh C, Barry, M. Pharmacoeconomics 2012; 30(10):941-959.
The Clinical and Economic Burden of Poor Adherence and Persistence with Osteoporosis Medications in Ireland
Hiligsmann M, McGowan B, Bennett K, Barry M, Reginster J-Y. Value in Health. 2012 Jul-Aug;15(5):604-12.
Cost-effectiveness of population-based screening for colorectal cancer: a comparison of guaiac-based faecal occult blood testing, faecal immunochemical testing and flexible sigmoidoscopy.
L Sharp, L Tilson, S Whyte, A O’Ceilleachair, C Walsh, C Usher, P Tappenden, J Chilcott, A Staines, M Barry and H Comber. Br J Cancer. 2012:106; 805-816.
Cost containment interventions introduced on the Community Drugs Schemes in Ireland-Evaluation of Expenditure Trends Using a National Prescription Claims Database.
C. Usher, L. Tilson, K. Bennett, M. Barry. Clinical Therapeutics 2012, 34(3):632-639.
A mixed treatment comparison of the efficacy of anti-TNF agents in rheumatoid arthritis for methotrexate non-responders demonstrates differences between treatments: a bayesian approach.
Schmitz S, Adams R, Walsh CD, Barry M, FitzGerald O. Ann Rheum Dis. 2012 Feb;71(2):225-30.
Cost of care of colorectal cancer in Ireland: a health care payer perspective.
Tilson L, Sharp L, Usher C et al. Eur J Health Econ. 2012 Aug;13(4):511-24.
